Kronos Bio Inc KRON

$0.88 +0.01 (1.49%)

Valuation

Market cap
53,725,000
Revenue TTM
$9,850,000
Net income TTM
$-86,080,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-873.91%
Debt to equity
0.00

Trading

Volume
54,000
Avg volume
1,037,404
Day's range
$0.87 – $0.88
Shares out
61,051,000
Stochastic %K
54%
Beta
1.63
Analysts
Strong Buy
Price target
$2.25

Price

Company profile

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in...

Show more

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California. As of June 20, 2025, Kronos Bio, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Industry
Biotechnology
Sector
Healthcare
Phone
650 781 5200
Website
https://www.kronosbio.com
Address
1300 So. El Camino Real, Suite 400, San Mateo, United States

Latest news